title: The effect of U-74389G on liver recovery after acute liver ischemia-reperfusion injury in a swine model.
abstract: BACKGROUND
  The potential of U-74389G in attenuating liver damage after ischemia and reperfusion of the liver was studied in a swine model.
  
  
  METHODS
  Eighteen pigs, weighting 28-35 kg, were used in the study. The animals were divided into the following three experimental groups: Group A (control group): Ischemia time 30 min and reperfusion for 120 min (with tissue and blood sampling at both 60 min (A-60) and 120 min (A-120)); Group B: Ischemia time 30 min, U-74389G intraportal injection, and reperfusion for 60 min; and Group C: Ischemia time 30 min, U-74389G intraportal injection, and reperfusion for 120 min. The dose of U-74389G administered was 10 mg/kg animal body weight. Anesthesia was induced with propofol, pancuronium, and fentanyl. Surgery was performed through a midline laparotomy. The portal vein and the common hepatic artery were isolated and prepared for occlusion.
  
  
  RESULTS
  Histopathological evaluation revealed a statistically significant difference in portal infiltration in the liver tissue between control group A-60 and group B (P = 0.01), and between control group A-120 and group C (P = 0.002). Hemodynamic and metabolic data in the control and therapy groups at 0, 30, 60, and 120 min were not statistically significantly different. Tissue malondialdehyde levels were statistically significantly different. Tumor necrosis factor-alpha values were statistically significantly different between groups A-60 and B but not between groups A-120 and C.
  
  
  CONCLUSIONS
  Based on the histological data and the reduction of the malondialdehyde and tumor necrosis factor-alpha levels, administration of U-74389G in ischemia-reperfusion injury of the liver in a swine model has potential in attenuating liver damage.
authors.affiliation: 2nd Department of Surgery, Medical School, Democritus University of Thrace, Alexandroupolis, Greece. tsihrin@otenet.gr
authors.forename: Alexandra K
authors.initials: AK
authors.lastname: Tsaroucha
authors.forename: Apostolos
authors.initials: A
authors.lastname: Papalois
authors.forename: Spyridon
authors.initials: S
authors.lastname: Vernadakis
authors.forename: Stavros
authors.initials: S
authors.lastname: Adamopoulos
authors.forename: Konstantinos
authors.initials: K
authors.lastname: Papadopoulos
authors.forename: Maria
authors.initials: M
authors.lastname: Lambropoulou
authors.forename: Theodoros
authors.initials: T
authors.lastname: Constadinidis
authors.forename: Avgi
authors.initials: A
authors.lastname: Kyriazi
authors.forename: Nikolaos
authors.initials: N
authors.lastname: Papadopoulos
authors.forename: Constantinos
authors.initials: C
authors.lastname: Simopoulos
mesh_terms: D000208:Acute Disease; D000818:Animals; D000975:Antioxidants / Q000494:pharmacology*; D004195:Disease Models, Animal; D006499:Hepatic Artery / Q000601:surgery; D008099:Liver / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D008315:Malondialdehyde / Q000378:metabolism; D011169:Portal Vein / Q000601:surgery; D011281:Pregnatrienes / Q000494:pharmacology*; D020127:Recovery of Function / Q000187:drug effects*; D015427:Reperfusion Injury / Q000378:metabolism*; D013552:Swine; D013997:Time Factors; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
chemical_list: D000975:Antioxidants; D011281:Pregnatrienes; D014409:Tumor Necrosis Factor-alpha; C074965:U 74389F; D008315:Malondialdehyde